ArticleResearch and practice in thrombosis and haemostasis2025
NXT007 enhances
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Factor Therapies in Haemophilia: The Era of Factor VIII Mimetics and Targeted Rebalancing Agents.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Divergent molecular strategies of next-generation activated factor VIII mimetics: insights from a direct comparative analysis.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In the future, emicizumab users may switch to NXT007. Objectives: To investigate the effects of NXT007 in the coexistence of emicizumab on coagulation potential Methods: Coagulation potentials of HA plasma were determined by thrombin generation (TG) assays. NXT007 binding was analyzed by biolayer interferometry (BLI) and immunoblotting. Plasma levels of FIX-BsAb-FX ternary complexes were simulated using dissociation constant values for calculating theoretical coagulation potentials. Results: In coexistence of emicizumab at 50 μg/mL (therapeutic concentration), NXT007 (0.1-100 μg/mL) dose-dependently increased TG capacity of HA plasma, similar to its effect without emicizumab. At 10-100 μg/mL of NXT007, TG capacity reached levels comparable to NXT007-only conditions. BLI analysis revealed that emicizumab and NXT007 could not simultaneously bind to the same antigens, indicating that only ternary complexes or lower stoichiometry can be formed from FIX(a), FX(a), emicizumab, and NXT007. Immunoblotting analyses confirmed both BsAbs recognized the same antigen domains. Therefore, plasma coagulation potential should be the sum of the contributions of both BsAbs. Our calculations in this manner were concordant with the TG results. Conclusion: NXT007 enhanced TG capacity of HA plasma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.